Moderna Inc. (MRNA)
Health Care34 articles
Price chart
Why is MRNA moving today?
-7.8%MRNA is -7.8% today, a large move, and no story about it reached the feed in the last 24 hours. Large moves without a headline are common: index flows, options positioning, a peer's report or a sector rotation can all do it. We do not invent a reason.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 8 hours ago
Moderna Inc. (MRNA) overview
Moderna is a biotech pioneering mRNA vaccines and therapeutics.
MRNA is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Moderna Inc. trades on the NasdaqGS under the ticker symbol MRNA. The most recent market data puts the share price at about $218.01. That is down 7.82% on the session. At that price the company is worth roughly $87.04B.
Over the past 52 weeks, MRNA has traded between $22.28 and $242.29.
Key statistics
Source: Yahoo Finance - quote as of 8 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MRNA
MRNA is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each MRNA story as it breaks, and tags it bullish, bearish or neutral.
What moves MRNA
- Earnings. MRNA reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from MRNA.
- Sector news. Health Care stocks often move together, so a rival's news can move MRNA too.
Market Mood
Latest MRNA news
10% of Cystic Fibrosis Patients Still Await Effective Treatment
Approximately 10% of cystic fibrosis patients do not benefit from recent advancements in CF treatments, which use drugs like Trikafta. These drugs, made by Vertex Pharmaceuticals, enhance the CFTR protein function for 90% of patients, transforming the disease into a more manageable condition. However, the remaining 10% of patients, born with other genetic mutations, experience a lack of effective treatment. Recent scientific efforts, including attempts by Vertex and Moderna using mRNA technology and Boehringer Ingelheim's gene therapy trials, were halted due to tolerability issues and other challenges. Emily's Entourage, a nonprofit founded by Emily Kramer-Golinkoff, has played a key role in continuing research for these patients. Since its inception in 2011, it has raised over $22 million, funding 51 research projects that explore novel treatments like antisense oligonucleotides and small molecules. Delivering drugs to affected lung cells poses significant scientific challenges because of the lungs' natural defenses and the presence of thick mucus in CF patients. This matters to ordinary investors as ongoing research might open opportunities for pharmaceutical companies to address the unmet needs of these patients, potentially leading to breakthroughs that could impact company valuations and future investment decisions.
Read More: 10% of Cystic Fibrosis Patients Still Await Effective Treatment
Robinhood (HOOD) Shares Surge in Premarket Trading Following News
Robinhood (HOOD) is experiencing significant movement prior to market opening, alongside notable stocks like Boeing and Moderna. While specific trading volumes or percentage changes for these companies were not mentioned, the article highlights the increased attention on Robinhood. Understanding these premarket activities may provide investors with insights on market trends and potential price adjustments. This is relevant for ordinary investors looking to assess trading opportunities based on premarket performance.
Read More: Robinhood (HOOD) Shares Surge in Premarket Trading Following News
Pfizer (PFE) and Moderna patent case against Bayer dismissed
Pfizer (PFE), BioNTech, and Moderna have lost their attempt to dismiss a patent infringement case brought by Bayer. The court's decision allows Bayer to pursue its claim related to the technology used in mRNA vaccines. This ruling may have implications for the patent landscape in the biopharmaceutical industry, potentially affecting how companies protect their innovations. The outcome could influence future litigation involving vaccine patents, which is valuable for investors in this sector.
Read More: Pfizer (PFE) and Moderna patent case against Bayer dismissed
Moderna (MRNA) to Reveal mRNA Cancer Vaccine Data Next Month
Moderna (MRNA) is set to disclose data regarding its mRNA cancer vaccine next month. Analysts and medical professionals are seeking this information to assess the effectiveness of the personalized treatment. The upcoming data release could provide insights into the vaccine's performance and potential impact on the cancer treatment landscape. This matters for investors as it could influence decisions regarding Moderna's future revenue potential driven by novel therapies.
Read More: Moderna (MRNA) to Reveal mRNA Cancer Vaccine Data Next Month
Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Moderna (MRNA) shares surged 9% to $168 after its Phase 3 melanoma vaccine study was selected for the Presidential Symposium slot at the European Society for Medical Oncology congress on October 24. Meanwhile, Merck (MRK) gained 1% and BioNTech (BNTX) increased 2%. The selection highlights the significance of the study, although no new efficacy data was released. This offers a signal to investors that the research may lead to practice-changing developments in cancer treatment, impacting Moderna's evaluation and future opportunities.
Read More: Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Dow Jones Futures and AI Oversight Ahead of Fed Meeting
Dow Jones futures will start trading on Sunday evening with significant attention on artificial intelligence leaders calling for a slowdown in AI model development. This comes amid concerns from figures like Anthropic's Amodei, OpenAI's Altman, and SpaceX's Musk regarding the risks associated with rapid AI advancements. The stock market experienced a fall last week but showed signs of recovery on Friday, with Apple (AAPL), Moderna (MRNA), and NetApp (NTAP) indicating buy signals. For ordinary investors, the market's reaction to the Fed meeting and AI developments could influence trading strategies and stock movements in the coming days.
Read More: Dow Jones Futures and AI Oversight Ahead of Fed Meeting
Apple (AAPL) Joins New Buy List as Rate Hike Pressures Stocks
Dow Jones Futures have reacted to expectations of a rate hike by the Federal Reserve while oil prices decrease. The Dow rose by 500 points, breaking a four-day decline. Analysts are pointing to a clearer Fed outlook as a factor influencing this change. Apple (AAPL) and Moderna are identified as new buying opportunities in this market environment, which may attract investors looking for potential growth amidst rising rates.
Read More: Apple (AAPL) Joins New Buy List as Rate Hike Pressures Stocks
Moderna (MRNA) Leads August with 156% Gain Amid Market Recovery
In August, several S&P 500 stocks rebounded sharply after facing months of bearish pressures. Moderna (MRNA) saw the highest gain, rising 156% due to promising results for its melanoma vaccine. Other significant winners included Palantir (PLTR) with a 51.45% increase and Veeva Systems (VEEV) at 40.2%. This market recovery is crucial as it highlights the resilience and potential growth in key sectors like biotechnology and enterprise software amid prior investor skepticism.
Read More: Moderna (MRNA) Leads August with 156% Gain Amid Market Recovery
Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) and Merck (MRK) have reported a breakthrough in developing a cancer vaccine aimed at preventing melanoma recurrence. This is a significant event, marking progress after a century of unsuccessful attempts in cancer vaccine research. The announcement highlights the collaboration between the two companies, potentially impacting their stock performance and investor interest. Investors may want to monitor the developments closely, as advancements in cancer treatment can influence market dynamics and investment strategies in the healthcare sector.
Read More: Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) FDA Approval of Updated COVID-19 Vaccines Confirmed
Moderna (MRNA) has received U.S. FDA approval for its updated COVID-19 vaccines for the 2026-2027 season. The approval comes as COVID-19 cases are reported to be rising, highlighting the ongoing health concerns. This event matters as it indicates continued governmental support for vaccine development amidst health challenges, which could influence market perceptions of Moderna's stock performance. The market impact may hinge on vaccination uptake and public response to the updated vaccines.
Read More: Moderna (MRNA) FDA Approval of Updated COVID-19 Vaccines Confirmed
Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.
Read More: Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) cancer vaccine shows positive breakthrough results
Moderna (MRNA) announced progress in its cancer vaccine trials, reviving interest in biotech ventures. The preliminary data suggests potential efficacy, which may ease concerns over previous performance setbacks. Investors are optimistic this development could lead to an upturn in shares, particularly in a sector still recovering from market volatility. The outcome of these trials may influence future biotech investments, highlighting the importance of innovation in the sector.
Read More: Moderna (MRNA) cancer vaccine shows positive breakthrough results
Moderna (MRNA) mRNA Shot May Change Skin Cancer Treatment Landscape
Moderna's (MRNA) personalized mRNA vaccine for skin cancer is generating significant interest among medical professionals and patients. While some analysts express enthusiasm about its potential, they caution that there may be excessive optimism surrounding this development. The ongoing conversations in the medical community highlight the importance of validating the effectiveness of such treatments before widespread adoption. For investors, the mixed opinions from analysts could indicate volatility in the stock’s performance as market expectations adjust.
Read More: Moderna (MRNA) mRNA Shot May Change Skin Cancer Treatment Landscape
Walmart (WMT) and Coinbase (COIN) Show Premarket Activity
Walmart (WMT) and Coinbase (COIN) are among stocks making significant moves in premarket trading. While specific numbers for these movements are not detailed in the article, it highlights a variety of companies, including Moderna and Alibaba, also involved in notable premarket activity. Premarket trading can indicate investor sentiment and possible stock price directions for the day. Monitoring these movements is essential for investors looking to capitalize on active stocks.
Read More: Walmart (WMT) and Coinbase (COIN) Show Premarket Activity
Moderna (MRNA) cancer-vaccine breakthrough drives biopharma rally
Moderna's (MRNA) recent advancements in cancer-vaccine development have contributed to a rally in the biopharmaceutical sector, which has been recovering from a prolonged downturn. The enthusiasm surrounding this breakthrough indicates a growing investor confidence within the industry. Although specific figures were not provided, the overall positive sentiment reflects a shift in market dynamics. This matters for ordinary investors as it signals potential growth opportunities in biopharma stocks, which could be beneficial for their portfolios.
Read More: Moderna (MRNA) cancer-vaccine breakthrough drives biopharma rallyModerna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
Merck and Moderna announced promising results from a late-stage trial of their cancer vaccine aimed at preventing melanoma recurrence. The trial demonstrated significant efficacy, contributing to a 150% surge in Moderna's stock price. This notable rise translates into a $5 billion loss for short sellers betting against the stock. The trial results mark a pivotal moment in cancer treatment, impacting market perceptions of both companies' potential in oncology therapeutics. This matters for investors as advancements in medical treatments can significantly influence stock valuations and future revenue streams for companies like Moderna (MRNA).
Read More: Moderna (MRNA) Cancer Vaccine Shows 150% Stock Surge PotentialModerna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna (MRNA) experienced a doubling in share price following positive outcomes from its late-stage melanoma vaccine trial developed in collaboration with Merck. This development is significant as it indicates potential advancements in cancer treatment and may attract investor interest. The success can impact market perceptions of biotechnology stocks, especially those involved in cancer therapies. Strong results in clinical trials can lead to increased funding and partnership opportunities for Moderna, influencing its future growth potential.
Read More: Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna Soars on Cancer News Amid S&P 500 Gains
The S&P 500 index is experiencing upward momentum as the Federal Reserve's minutes are anticipated. Moderna (MRNA) has responded positively to news regarding progress in cancer treatment. The reception of this news could affect investor confidence and market dynamics going forward. This upward trend in Moderna's stock may attract investor interest amid broader market movements.
Read More: Moderna Soars on Cancer News Amid S&P 500 Gains
Stocks Making Big Moves: Moderna, Pilgrim's Pride, Target
Several companies are experiencing significant stock movements. Moderna shares are moving due to recent developments in its vaccine pipeline, while Pilgrim's Pride is affected by changes in consumer demand. Target's stock reaction stems from recent financial performance reports. This volatility highlights current market trends and investor sentiment, impacting investment strategies for those focused on these companies.
Read More: Stocks Making Big Moves: Moderna, Pilgrim's Pride, TargetModerna (MRNA) cancer vaccine trial shows positive early results
In its first late-stage trial, a personalized cancer vaccine from Moderna (MRNA) and Merck showed positive results. The trial involved over 1,100 patients with higher-risk melanoma and met key goals, significantly extending time until cancer recurrence compared to Keytruda alone. Following the announcement, Merck's stock rose over 8% and Moderna's shares soared about 100%. The trial's success suggests that this combination could be a significant new treatment option for melanoma, impacting future drug development and potential market dynamics for these companies.
Read More: Moderna (MRNA) cancer vaccine trial shows positive early results
Premarket Stock Moves: Zillow, Peloton, Sandisk, Moderna Update
The premarket trading session saw significant movements in multiple stocks. Notable companies included Zillow, Peloton, Sandisk, and Moderna. Details on specific trading volumes or percentage changes were not provided. These movements can impact overall market trends and investor sentiment. Monitoring these fluctuations is important for investors looking to capitalize on premarket activity.
Read More: Premarket Stock Moves: Zillow, Peloton, Sandisk, Moderna Update
Apple (AAPL) and other Stocks Showing Notable Premarket Moves
In the premarket, several stocks including Apple (AAPL), Chevron, Amazon, and Moderna are experiencing notable moves. Replimune, Chevron, and other companies featured in the list could indicate changes in investor sentiment. Watching these stocks might reveal shifts that can impact market performance. This information is valuable for investors looking to make informed trading decisions based on premarket activity.
Read More: Apple (AAPL) and other Stocks Showing Notable Premarket Moves
Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.
Read More: Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
In FY 2025, Moderna (MRNA) reported revenue exceeding $1.9 billion, a 40% decrease from the prior year, alongside a net loss of approximately $2.8 billion. The company's debt-to-equity ratio was about 0.2x, and free cash flow was nearly $2.1 billion negative. In comparison, Recursion Pharmaceuticals (RXRX) generated approximately $74.7 million in revenue, marking a 27% year-over-year increase, but recorded a net loss of nearly $645 million. Its debt-to-equity ratio stood at around 0.1x, with free cash flow of about negative $378 million, indicating significant investment in its infrastructure.
Read More: Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) and ON Semiconductor (ON) were highlighted among stocks making significant midday moves. Although the article mentions several companies, specific data points, metrics, or trading volumes are not provided regarding these stock movements. Such notable movements can impact investor sentiment and potential trading strategies. Without verifiable events or figures, the overall market implications remain unclear.
Read More: Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
A key FDA advisory panel has unanimously recommended Moderna's (MRNA) mRNA flu vaccine, marking the first of its kind since 2023. This recommendation is significant as it could pave the way for regulatory approval, enhancing Moderna's portfolio and potentially impacting market positioning against competitors. The vaccine is designed specifically for older adults, addressing a critical healthcare need. The panel's endorsement follows discussions regarding the vaccine's efficacy and safety, which may influence investor sentiment in the biopharmaceutical sector.
Read More: Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
The FDA advisory panel voted unanimously to approve Moderna's (MRNA) mRNA flu vaccine for older adults. This decision may impact the market by potentially increasing demand for Moderna's vaccine offerings. The mRNA flu vaccine is expected to enhance B cell response breadth in humans, a factor that could improve public health outcomes. The approval comes after prior controversies surrounding the vaccine's deployment, adding weight to the FDA's endorsement.
Read More: Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) experienced significant stock movement following news of a peace deal in Iran, which positively influenced market sentiment. This development contributed to a rise in the Dow Jones Industrial Average, further supported by bullish trends in AI stocks. The market is observing a shift in trading volumes, but specific numbers were not detailed. Overall, the implications of the Iran agreement on broader market conditions may indicate increased investor confidence.
Read More: Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
On June 15, Moderna (MRNA) filed Form 144, a document indicating the intention to sell shares of its common stock. This filing reflects potential insider selling, which can impact investor sentiment and market perceptions. Understanding the volume and timing of these sales is crucial for assessing the company's stock performance. The details of shares sold or the significance of this transaction will be closely monitored by investors for any potential effects on MRNA's market behavior.
Read More: Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
The US FDA announced it will hold a meeting with an expert committee to review the flu vaccine developed by Moderna (MRNA). This meeting is crucial as it will assess the vaccine's efficacy and safety. Given the increasing interest in flu vaccinations, particularly in the context of ongoing health concerns, this evaluation may impact market perception of Moderna's future revenues. The outcome of the review could influence both Moderna's stock performance and broader market trends in the biotech sector.
Read More: Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) is currently under scrutiny regarding its profitability as the company's revenue streams face challenges. The latest reports indicate a significant decrease in demand for its COVID-19 vaccine, leading to a projected revenue drop of 70% for 2023 compared to 2022. Given these developments, experts are closely monitoring MRNA's financial stability and operational adjustments. The ongoing analysis could impact the biotech sector as investors evaluate the company's future prospects.
Read More: Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Several stocks, including Moderna (MRNA), Lumentum, Intel, and monday.com, are experiencing notable movements in premarket trading. However, concrete data points such as trading volumes or percentage changes have not been reported in this article. The market impact of these movements remains unclear due to the lack of specific figures or insights into the reasons behind the fluctuations. Monitoring these stocks could provide insights into broader market trends and investor sentiment.
Read More: Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Following the World Health Organization's announcement of a hantavirus outbreak on May 2, several pharmaceutical stocks, including Moderna (MRNA), experienced significant gains. Moderna's shares increased by 7% in premarket trading as the company is conducting preclinical research on the hantavirus. Inovio Pharmaceuticals reported a 13% rise, while Emergent Biosolutions and Novavax gained 4% and 3%, respectively. Analysts from Evercore ISI suggested that any revenue potential for Moderna related to hantavirus is unlikely, viewing stock movements as sentiment-driven rather than fundamentally driven.
Read More: Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Market Movers: Moderna Settles COVID Patent Dispute, Boosting Stock Value
Moderna's shares surged following the announcement of a $2.25 billion settlement related to a COVID vaccine patent dispute, which alleviated concerns about potential legal liabilities affecting its future. This settlement, which includes a $1 billion payment to settle litigation with Arbutus, removes a significant overhang from the company's stock, potentially restoring investor confidence. Meanwhile, Coinbase and other cryptocurrency stocks also experienced notable gains, contributing to an overall positive sentiment in the markets, as optimism around the crypto sector appears to be gaining traction. The combination of these developments may lead to increased trading volumes and heightened investor interest in both healthcare and cryptocurrency sectors.
Read More: Market Movers: Moderna Settles COVID Patent Dispute, Boosting Stock ValueMore Health Care stocks
Frequently asked questions
Is Moderna Inc. in the S&P 500?
Yes. Moderna Inc. trades as MRNA and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is MRNA in?
MRNA sits in the Health Care sector of the S&P 500.
Where can I find the latest MRNA news?
Right here. This page collects recent MRNA news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Moderna Inc.'s stock price?
MRNA last traded at about $218.01. Prices move all through the session, so this is the latest quote rather than a live one.
What is Moderna Inc.'s market cap?
MRNA is worth roughly $87.04B. Market cap is the share price times the number of shares outstanding.